Publications by authors named "Noriko Sakasegawa"
Background: To determine whether central and in vitro administration of urocortin 2 (Ucn 2) affected intestinal inflammatory responses in LPS-stimulated rat models and macrophage cell lines and acotiamide modified mucosal inflammation in this model.
Methods: Rats were divided into four groups. LPS-stimulated group (n = 4); LPS- and urocortin 2-treated group (n = 4); LPS- and acotiamide-treated group (n = 4); and LPS-, urocortin 2-, and acotiamide-treated group (n = 4).
Background: There was no available data concerning the clinical differentiation between the updated definition of early chronic pancreatitis (ECP) and anti-acid therapy-resistant functional dyspepsia (RFD).
Aims: We aimed to determine whether clinical symptoms, gastric motility, psychogenic factors and fat intake can help distinguish early chronic pancreatitis (ECP) from anti-acid therapy-resistant functional dyspepsia patients with pancreatic enzyme abnormalities (RFD-P) and anti-acid therapy-resistant functional dyspepsia (RFD) patients using endosonography.
Methods: We enrolled 102 consecutive patients presenting with typical symptoms of RFD patients (n = 52), ECP patients (n = 25) and RFD-P patients (n = 25).
Article Synopsis
- The study aims to investigate the pathophysiological differences between early chronic pancreatitis (ECP), functional dyspepsia with pancreatic enzyme abnormalities (FD-P), and functional dyspepsia (FD), and to assess the effectiveness of a triple therapy involving camostat mesilate, pancrelipase, and rabeprazole in improving FD symptoms among these patients.
- A total of 84 patients were enrolled, including those with FD, ECP, and FD-P, and gastric emptying was measured using a specific breath test.
- The results showed that ECP and FD-P patients had greater female representation and more significant gastric emptying disturbances than FD patients; the triple therapy notably reduced epigastric pain in E
New classification Rome IV functional dyspepsia and subtypes.
Transl Gastroenterol Hepatol
September 2018
Management of functional dyspepsia: state of the art and emerging therapies.
Ther Adv Chronic Dis
January 2018
Patients with functional dyspepsia, defined in the 2016 Rome IV criteria as bothersome clinical dyspepsia symptoms, experience markedly reduced quality of life. Several etiologies have been associated with the disorder. In the Rome IV criteria, the brain-gut axis was acknowledged as an important factor in the etiology of functional gastrointestinal (GI) disorders.
View Article and Find Full Text PDFArticle Synopsis
- Researchers created a new cell line called HPI cells to study HCV (Hepatitis C virus) infections in a stable environment, unlike traditional lytic systems that kill off infected cells.
- Over two years, HPI cells exhibited significant metabolic changes, including increased cholesterol and fatty acid levels, along with activity in metabolic pathways like the pentose phosphate pathway.
- The study identified that Nrf2, a key regulator of metabolism and antioxidation, plays a critical role in sustaining HCV infection and metabolic alterations in these cells, making HPI an important tool for future research.
The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) has a clinical promise for treatment of cancer including hepatocellular carcinoma (HCC). To investigate effect of SAHA on hepatitis C virus (HCV) replication, we treated the HCV replicon cell OR6 with SAHA. HCV replication was significantly inhibited by SAHA at concentrations below 1 μM with no cellular toxicity.
View Article and Find Full Text PDF